We hope to see you again soon!
You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
The content on this page is intended for members of the public.
Products
Names and Compounds of our Products
Report An Adverse Event:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Adverse events should also be reported to Lundbeck Limited, Medical Information on 01908 638972 or at SafetyLuUnitedKingdom@lundbeck.com.
Lundbeck Ltd UK Distributed or Promoted Products
All our products are prescription-only medicines (POM). If more information is required, please refer to the local Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) using the links below.
For Abilify® (aripiprazole) and Abilify Maintena® (aripiprazole), medicines which are marketed jointly with Otsuka who are the Marketing Authorisation (MA) holder, please use the links below. All other medicines can be found at the links above.
More from lundbeck
R&D of new and improved treatments is at the core of what we do.
We see patients as people and are committed to support the person behind.
Discover our projects and compounds in development.
UK-NOTPR-1780 | February 2024